Yale University

Celldex Therapeutics Limited

Yan Yang

Joseph Schlessinger

Francis Joseph Carr

Timothy David Jones

Yaron R Hadari

Robert George Edward Holgate

Irit Lax

Satoru Yuzawa

Yarden Opatowsky

Richard Weldon

Lida Kimmel

Brett Robinson

Sreekala Mandiyan

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.

Anti-MET antibodies and methods of use thereof

The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.

Inhibitors of receptor tyrosine kinases and methods of use thereof

Growing community of inventors

Hamden, CT, United States of America

Yan Yang